LYEL vs. ALEC, VERV, ERAS, ALLO, BCYC, AGIO, ACAD, JANX, GPCR, and INDV
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Alector (ALEC), Verve Therapeutics (VERV), Erasca (ERAS), Allogene Therapeutics (ALLO), Bicycle Therapeutics (BCYC), Agios Pharmaceuticals (AGIO), ACADIA Pharmaceuticals (ACAD), Janux Therapeutics (JANX), Structure Therapeutics (GPCR), and Indivior (INDV). These companies are all part of the "medical" sector.
Alector (NASDAQ:ALEC) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment.
Alector has higher revenue and earnings than Lyell Immunopharma. Alector is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Alector received 133 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 60.58% of users gave Alector an outperform vote while only 56.52% of users gave Lyell Immunopharma an outperform vote.
Alector has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500.
Alector has a net margin of -125.11% compared to Alector's net margin of -335,794.09%. Alector's return on equity of -33.92% beat Lyell Immunopharma's return on equity.
85.8% of Alector shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 9.1% of Alector shares are held by insiders. Comparatively, 25.1% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Alector had 6 more articles in the media than Lyell Immunopharma. MarketBeat recorded 8 mentions for Alector and 2 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.41 beat Alector's score of 0.00 indicating that Alector is being referred to more favorably in the media.
Alector presently has a consensus price target of $14.00, suggesting a potential upside of 221.10%. Lyell Immunopharma has a consensus price target of $5.50, suggesting a potential upside of 126.34%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Alector is more favorable than Lyell Immunopharma.
Summary
Alector beats Lyell Immunopharma on 13 of the 18 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
